オリゴヌクレオチド療法の世界市場レポート 2024年

オリゴヌクレオチド療法の市場規模は、今後数年間で急速に成長すると予想されています。 2028年には11.8%の年間複合成長率（CAGR）で87億5,000万米ドルに成長すると予想されます。予測期間の拡大は、研究開発、世界市場浸透、治療領域の拡大、疾患改善戦略、規制適応への投資の増加に起因すると考えられます。予測期間の主要動向には、個別化治療、送達システムの進歩、RNA干渉（RNAi）の革新、アンチセンスオリゴヌクレオチドの進歩、遺伝子編集技術の統合が含まれます。

世界のがん症例の増加は、予測期間中のオリゴヌクレオチド療法市場の成長に寄与すると予想されます。たとえば、2022年 1月の時点で、米国がん協会は、米国で約190万人が新たにがんと診断され、60万9,360人ががん関連で死亡し、1日あたり平均約1,670人が死亡すると予測しています。世界中で最も蔓延しているがんの種類である肺がん、前立腺がん、腸がん、と女性の乳がんは、新規がん症例全体の43%を占めています。その結果、世界のがん罹患率の急増により、今後数年間でオリゴヌクレオチド療法市場の需要が高まると考えられます。

医療の研究開発を目的とした政府の取り組みにより、オリゴヌクレオチド療法市場の成長が促進されると予想されます。これらの取り組みには、特定の問題に対処したり、定義された目標を達成したり、社会に前向きな変化を促したりするために、さまざまなレベル（地方、地域、国家、または国際）で政府当局が実施する特定の行動、プログラム、政策、またはプロジェクトが含まれます。さまざまな政府機関が、オリゴヌクレオチド療法などのさまざまな側面をサポートする医療イニシアチブを立ち上げています。保健社会福祉省によると、英国政府は2022年に医療の調査と製造を強化するために2億6,000万ポンド（2億7,065万米ドル）の資金提供を約束しました。 BEISとDHSCによって提供されたこの資金は、新しいプライバシー保護プラットフォームと臨床研究サービスを通じて、診断と治療におけるNHS主導の健康調査を支援することを目的としていました。さらに、英国におけるライフサイエンス製造業の拡大を支援するために、6,000万ポンド（6,360万米ドル）が割り当てられました。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 マクロ経済シナリオ

• 高インフレが市場に与える影響
• ウクライナ・ロシア戦争が市場に与える影響
• COVID-19による市場への影響

第5章 世界市場規模と成長

• 世界のオリゴヌクレオチド療法市場の促進要因と抑制要因
  • 市場促進要因
  • 市場抑制要因
• 世界のオリゴヌクレオチド療法市場規模実績と成長、2018～2023年
• 世界のオリゴヌクレオチド療法市場規模と成長予測、2023～2028年、2033年

第6章 市場セグメンテーション

• 世界のオリゴヌクレオチド療法市場、タイプ別セグメンテーション、実績と予測、2018～2023年、2023～2028年、2033年
• アンチセンスオリゴヌクレオチド
• アプタマー
• その他
• 世界のオリゴヌクレオチド療法市場、用途別セグメンテーション、実績と予測、2018～2023年、2023～2028年、2033年
• 感染症
• 腫瘍
• 神経変性疾患
• 心血管疾患
• 腎臓病
• その他
• 世界のオリゴヌクレオチド療法市場、エンドユーザー別セグメンテーション、実績と予測、2018～2023年、2023～2028年、2033年
• 病院
• 研究機関

第7章 地域と国の分析

• 世界のオリゴヌクレオチド療法市場、地域別、実績と予測、2018～2023年、2023～2028年、2033年
• 世界のオリゴヌクレオチド療法市場、国別、実績と予測、2018～2023年、2023～2028年、2033年

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• オリゴヌクレオチド療法市場の競合情勢
• オリゴヌクレオチド療法市場の企業プロファイル
  • Pfizer Inc.
  • Merck &Co. Inc.
  • GlaxoSmithKline plc
  • Gelead Sciences Inc.
  • BioNTech SE

第31章 その他の大手と革新的な企業

• Moderna Inc.
• Biogen Inc.
• Bausch+Lomb Company
• Jazz Pharmaceuticals plc
• QIAGEN Company
• Alnylam Pharmaceuticals Inc.
• Sarepta Therapeutics Inc.
• Dynavax Technologies Corp.
• Ionis Pharmaceuticals Inc.
• Akcea Therapeutics Inc.
• Arrowhead Pharmaceuticals Inc.
• Dicerna Pharmaceuticals lnc.
• SomaGenics Inc.
• Wave Life Sciences Ltd.
• Exicure Inc.

第32章 競合ベンチマーキング

第33章 競合ダッシュボード

第34章 主要な合併と買収

第35章 将来の展望と潜在性分析

第36章 付録

Oligonucleotide therapy is a comprehensive term encompassing advanced molecular-targeting agents that utilize chemically synthesized oligonucleotides featuring single-stranded DNA (DNA) or RNA (RNA) backbones with inherent selectivity. Oligonucleotides are designed to form base pairs with DNA or RNA strands for various applications, with their most prevalent use being in PCR primers (polymerase chain reaction).

The primary categories of oligonucleotide therapy include antisense oligonucleotides, aptamers, and others. Antisense oligonucleotides (AS ONs) are artificial DNA oligomers designed to hybridize with a specific target RNA sequence. They have proven effective in limiting gene expression, modifying precursor messenger RNA splicing, and deactivating microRNAs. This therapeutic approach finds applications in infectious diseases, oncology, neurodegenerative disorders, cardiovascular diseases, kidney diseases, among others, and is applied in healthcare facilities and research institutes.

The oligonucleotide therapy market research report is one of a series of new reports from The Business Research Company that provides oligonucleotide therapy market statistics, including oligonucleotide industry global market size, regional shares, competitors with an oligonucleotide market share, detailed oligonucleotide therapy market segments, market trends, and opportunities, and any further data you may need to thrive in the oligonucleotide industry. This oligonucleotide therapy market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The oligonucleotide therapy market size has grown rapidly in recent years. It will grow from $4.9 billion in 2023 to $5.61 billion in 2024 at a compound annual growth rate (CAGR) of 14.4%. The expansion in the historical period can be attributed to increased investments in research and development, the introduction of early therapies to the market, advancements in gene editing techniques, initial therapeutic discoveries, and the introduction of RNAi and antisense oligonucleotides.

The oligonucleotide therapy market size is expected to see rapid growth in the next few years. It will grow to $8.75 billion in 2028 at a compound annual growth rate (CAGR) of 11.8%. The expansion in the forecast period can be attributed to increased investments in research and development, global market penetration, the expansion of therapeutic areas, strategies for disease modification, and regulatory adaptations. Major trends in the forecast period include personalized therapies, advancements in delivery systems, innovations in RNA interference (RNAi), advancements in antisense oligonucleotides, and the integration of gene editing techniques.

The increase in cancer cases globally is expected to contribute to the oligonucleotide therapy market's growth during the forecast period. For example, as of January 2022, the American Cancer Society projected approximately 1.9 million new cancer diagnoses and 609,360 cancer-related deaths in the US, averaging around 1,670 fatalities daily. The most prevalent cancer types globally-lung, prostate, bowel, and female breast cancer-constitute 43% of all new cancer cases. Consequently, the surge in global cancer incidence rates is poised to drive the oligonucleotide therapy market's demand in the coming years.

Government initiatives aimed at research and development in healthcare are anticipated to boost the oligonucleotide therapy market's growth. These initiatives involve specific actions, programs, policies, or projects undertaken by government authorities at various levels (local, regional, national, or international) to address specific issues, achieve defined goals, or instigate positive changes in society. Various government bodies are launching healthcare initiatives to support different aspects, including oligonucleotide therapy. In 2022, the UK government, as per the Department of Health and Social Care, committed £260 million (US $270.65 million) in funding to enhance healthcare research and manufacturing. This funding, provided by BEIS and DHSC, aimed to support NHS-led health research in diagnostics and treatment through new privacy-preserving platforms and clinical research services. Additionally, £60 million (US $63.60 million) was allocated to assist in expanding life sciences manufacturing in the UK.

The oligonucleotide therapy market faced challenges during the forecast period due to the FDA's limited number of drug approvals. In 2022, the National Library of Medicine reported that only 37 new drug entities were approved, marking the lowest number since 2016. This can be attributed to stringent manufacturing standards and high efficacy criteria set by regulatory bodies for therapy approval, leading to prolonged approval timelines and restricting market growth.

Developers and providers in the oligonucleotide therapy market are investing in research and development to redesign therapy approaches. Innovative oligonucleotides enable precision medicine, selectively targeting genes with minimal side effects, and addressing patient-specific sequences causing rare diseases. In April 2023, the FDA approved Qalsody, an antisense oligonucleotide (ASO), for treating ALS associated with the SOD1 gene mutation. Qalsody targets SOD1 mRNA to reduce protein synthesis.

Major companies in the oligonucleotide therapy market are introducing pediatric-focused therapies to drive market revenues. Elevidys, the first FDA-approved gene therapy for Duchenne muscular dystrophy (DMD) in pediatric patients aged 4 through 5, showcases advancements in gene-based treatments for genetic diseases, although not specifically an oligonucleotide therapy.

In September 2022, Vanda Pharmaceuticals, a US-based biopharmaceutical company, and OliPass, a South Korea-based biotechnology company, announced a strategic partnership to develop antisense oligonucleotide (ASO) therapeutics. This collaboration aims to jointly develop a series of ASO molecules based on OliPass' proprietary modified peptide nucleic acids, leveraging the strengths of both companies to advance ASO-based precision medicine therapeutics.

Major companies operating in the oligonucleotide therapy market report are Pfizer Inc., Merck & Co. Inc., GlaxoSmithKline PLC, Gelead Sciences Inc., BioNTech SE, Moderna Inc., Biogen Inc., Bausch + Lomb Company, Jazz Pharmaceuticals PLC, QIAGEN Company, Alnylam Pharmaceuticals Inc., Sarepta Therapeutics Inc., Dynavax Technologies Corp., Ionis Pharmaceuticals Inc., Akcea Therapeutics Inc., Arrowhead Pharmaceuticals Inc., Dicerna Pharmaceuticals lnc., SomaGenics Inc., Wave Life Sciences Ltd., Exicure Inc., Hepion Phrmaceuticals lnc., Avidity Biosciences lnc., Miragen Therapeuutics Inc., ProQR Therapeutics NV, Regulus Therapeutics Inc., PCI Biotech Holdings ASA, Kastle Therapeutics LLC, Santaris Pharma A/S, InteRNA Technologies B.V., Dynacure S.A., Arcturus Therapeutics Holdings Inc., Intellia Therapeutics Inc., Regeneron Pharmaceuticals Inc., Editas Medicine Inc., Evox Therapeutics Ltd., ONK Therapeutics Ltd., PepGen Ltd.

North America was the largest region in the oligonucleotide therapy market in 2023. The regions covered in the oligonucleotide therapy market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the oligonucleotide therapy market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain

The oligonucleotide therapy market consists of sales of ASOs, siRNAs, miRNAs, and DNAzymes. Values in this market are factory gate values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Oligonucleotide Therapy Global Market Report 2024 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on oligonucleotide therapy market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 50+ geographies.
• Understand how the market has been affected by the coronavirus and how it is responding as the impact of the virus abates.
• Assess the Russia - Ukraine war's impact on agriculture, energy and mineral commodity supply and its direct and indirect impact on the market.
• Measure the impact of high global inflation on market growth.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 3-5 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for oligonucleotide therapy ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The oligonucleotide therapy market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The impact of sanctions, supply chain disruptions, and altered demand for goods and services due to the Russian Ukraine war, impacting various macro-economic factors and parameters in the Eastern European region and its subsequent effect on global markets.

The impact of higher inflation in many countries and the resulting spike in interest rates.

The continued but declining impact of covid 19 on supply chains and consumption patterns.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

Markets Covered:

• 1) By Type: Antisense Oligonucleotide; Aptamer; Other Types
• 2) By Application: Infectious Diseases; Oncology; Neurodegenerative Disorders; Cardiovascular Diseases; Kidney Diseases; Other End-User
• 3) By End User: Hospitals; Research Institutes
• Companies Mentioned: Pfizer Inc.; Merck & Co. Inc.; GlaxoSmithKline plc; Gelead Sciences Inc.; BioNTech SE
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Oligonucleotide Therapy Market Characteristics

3. Oligonucleotide Therapy Market Trends And Strategies

4. Oligonucleotide Therapy Market - Macro Economic Scenario

• 4.1. Impact Of High Inflation On The Market
• 4.2. Ukraine-Russia War Impact On The Market
• 4.3. COVID-19 Impact On The Market

5. Global Oligonucleotide Therapy Market Size and Growth

• 5.1. Global Oligonucleotide Therapy Market Drivers and Restraints
  • 5.1.1. Drivers Of The Market
  • 5.1.2. Restraints Of The Market
• 5.2. Global Oligonucleotide Therapy Historic Market Size and Growth, 2018 - 2023, Value ($ Billion)
• 5.3. Global Oligonucleotide Therapy Forecast Market Size and Growth, 2023 - 2028, 2033F, Value ($ Billion)

6. Oligonucleotide Therapy Market Segmentation

• 6.1. Global Oligonucleotide Therapy Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• Antisense Oligonucleotide
• Aptamer
• Other Types
• 6.2. Global Oligonucleotide Therapy Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• Infectious Diseases
• Oncology
• Neurodegenerative Disorders
• Cardiovascular Diseases
• Kidney Diseases
• Other End-User
• 6.3. Global Oligonucleotide Therapy Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• Hospitals
• Research Institutes

7. Oligonucleotide Therapy Market Regional And Country Analysis

• 7.1. Global Oligonucleotide Therapy Market, Split By Region, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 7.2. Global Oligonucleotide Therapy Market, Split By Country, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

8. Asia-Pacific Oligonucleotide Therapy Market

• 8.1. Asia-Pacific Oligonucleotide Therapy Market Overview
• Region Information, Impact Of COVID-19, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Oligonucleotide Therapy Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 8.3. Asia-Pacific Oligonucleotide Therapy Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 8.4. Asia-Pacific Oligonucleotide Therapy Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

9. China Oligonucleotide Therapy Market

• 9.1. China Oligonucleotide Therapy Market Overview
• 9.2. China Oligonucleotide Therapy Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
• 9.3. China Oligonucleotide Therapy Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
• 9.4. China Oligonucleotide Therapy Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion

10. India Oligonucleotide Therapy Market

• 10.1. India Oligonucleotide Therapy Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 10.2. India Oligonucleotide Therapy Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 10.3. India Oligonucleotide Therapy Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

11. Japan Oligonucleotide Therapy Market

• 11.1. Japan Oligonucleotide Therapy Market Overview
• 11.2. Japan Oligonucleotide Therapy Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 11.3. Japan Oligonucleotide Therapy Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 11.4. Japan Oligonucleotide Therapy Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

12. Australia Oligonucleotide Therapy Market

• 12.1. Australia Oligonucleotide Therapy Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 12.2. Australia Oligonucleotide Therapy Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 12.3. Australia Oligonucleotide Therapy Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

13. Indonesia Oligonucleotide Therapy Market

• 13.1. Indonesia Oligonucleotide Therapy Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 13.2. Indonesia Oligonucleotide Therapy Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 13.3. Indonesia Oligonucleotide Therapy Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

14. South Korea Oligonucleotide Therapy Market

• 14.1. South Korea Oligonucleotide Therapy Market Overview
• 14.2. South Korea Oligonucleotide Therapy Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 14.3. South Korea Oligonucleotide Therapy Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 14.4. South Korea Oligonucleotide Therapy Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

15. Western Europe Oligonucleotide Therapy Market

• 15.1. Western Europe Oligonucleotide Therapy Market Overview
• 15.2. Western Europe Oligonucleotide Therapy Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 15.3. Western Europe Oligonucleotide Therapy Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 15.4. Western Europe Oligonucleotide Therapy Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

16. UK Oligonucleotide Therapy Market

• 16.1. UK Oligonucleotide Therapy Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 16.2. UK Oligonucleotide Therapy Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 16.3. UK Oligonucleotide Therapy Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

17. Germany Oligonucleotide Therapy Market

• 17.1. Germany Oligonucleotide Therapy Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 17.2. Germany Oligonucleotide Therapy Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 17.3. Germany Oligonucleotide Therapy Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

18. France Oligonucleotide Therapy Market

• 18.1. France Oligonucleotide Therapy Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 18.2. France Oligonucleotide Therapy Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 18.3. France Oligonucleotide Therapy Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

19. Italy Oligonucleotide Therapy Market

• 19.1. Italy Oligonucleotide Therapy Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 19.2. Italy Oligonucleotide Therapy Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 19.3. Italy Oligonucleotide Therapy Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

20. Spain Oligonucleotide Therapy Market

• 20.1. Spain Oligonucleotide Therapy Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 20.2. Spain Oligonucleotide Therapy Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 20.3. Spain Oligonucleotide Therapy Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

21. Eastern Europe Oligonucleotide Therapy Market

• 21.1. Eastern Europe Oligonucleotide Therapy Market Overview
• 21.2. Eastern Europe Oligonucleotide Therapy Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 21.3. Eastern Europe Oligonucleotide Therapy Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 21.4. Eastern Europe Oligonucleotide Therapy Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

22. Russia Oligonucleotide Therapy Market

• 22.1. Russia Oligonucleotide Therapy Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 22.2. Russia Oligonucleotide Therapy Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 22.3. Russia Oligonucleotide Therapy Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

23. North America Oligonucleotide Therapy Market

• 23.1. North America Oligonucleotide Therapy Market Overview
• 23.2. North America Oligonucleotide Therapy Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 23.3. North America Oligonucleotide Therapy Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 23.4. North America Oligonucleotide Therapy Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

24. USA Oligonucleotide Therapy Market

• 24.1. USA Oligonucleotide Therapy Market Overview
• 24.2. USA Oligonucleotide Therapy Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 24.3. USA Oligonucleotide Therapy Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 24.4. USA Oligonucleotide Therapy Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

25. Canada Oligonucleotide Therapy Market

• 25.1. Canada Oligonucleotide Therapy Market Overview
• 25.2. Canada Oligonucleotide Therapy Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 25.3. Canada Oligonucleotide Therapy Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 25.4. Canada Oligonucleotide Therapy Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

26. South America Oligonucleotide Therapy Market

• 26.1. South America Oligonucleotide Therapy Market Overview
• 26.2. South America Oligonucleotide Therapy Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 26.3. South America Oligonucleotide Therapy Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 26.4. South America Oligonucleotide Therapy Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

27. Brazil Oligonucleotide Therapy Market

• 27.1. Brazil Oligonucleotide Therapy Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 27.2. Brazil Oligonucleotide Therapy Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 27.3. Brazil Oligonucleotide Therapy Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

28. Middle East Oligonucleotide Therapy Market

• 28.1. Middle East Oligonucleotide Therapy Market Overview
• 28.2. Middle East Oligonucleotide Therapy Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 28.3. Middle East Oligonucleotide Therapy Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 28.4. Middle East Oligonucleotide Therapy Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

29. Africa Oligonucleotide Therapy Market

• 29.1. Africa Oligonucleotide Therapy Market Overview
• 29.2. Africa Oligonucleotide Therapy Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 29.3. Africa Oligonucleotide Therapy Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 29.4. Africa Oligonucleotide Therapy Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

30. Oligonucleotide Therapy Market Competitive Landscape And Company Profiles

• 30.1. Oligonucleotide Therapy Market Competitive Landscape
• 30.2. Oligonucleotide Therapy Market Company Profiles
  • 30.2.1. Pfizer Inc.
    • 30.2.1.1. Overview
    • 30.2.1.2. Products and Services
    • 30.2.1.3. Strategy
    • 30.2.1.4. Financial Performance
  • 30.2.2. Merck & Co. Inc.
    • 30.2.2.1. Overview
    • 30.2.2.2. Products and Services
    • 30.2.2.3. Strategy
    • 30.2.2.4. Financial Performance
  • 30.2.3. GlaxoSmithKline plc
    • 30.2.3.1. Overview
    • 30.2.3.2. Products and Services
    • 30.2.3.3. Strategy
    • 30.2.3.4. Financial Performance
  • 30.2.4. Gelead Sciences Inc.
    • 30.2.4.1. Overview
    • 30.2.4.2. Products and Services
    • 30.2.4.3. Strategy
    • 30.2.4.4. Financial Performance
  • 30.2.5. BioNTech SE
    • 30.2.5.1. Overview
    • 30.2.5.2. Products and Services
    • 30.2.5.3. Strategy
    • 30.2.5.4. Financial Performance

31. Oligonucleotide Therapy Market Other Major And Innovative Companies

• 31.1. Moderna Inc.
• 31.2. Biogen Inc.
• 31.3. Bausch + Lomb Company
• 31.4. Jazz Pharmaceuticals plc
• 31.5. QIAGEN Company
• 31.6. Alnylam Pharmaceuticals Inc.
• 31.7. Sarepta Therapeutics Inc.
• 31.8. Dynavax Technologies Corp.
• 31.9. Ionis Pharmaceuticals Inc.
• 31.10. Akcea Therapeutics Inc.
• 31.11. Arrowhead Pharmaceuticals Inc.
• 31.12. Dicerna Pharmaceuticals lnc.
• 31.13. SomaGenics Inc.
• 31.14. Wave Life Sciences Ltd.
• 31.15. Exicure Inc.

32. Global Oligonucleotide Therapy Market Competitive Benchmarking

33. Global Oligonucleotide Therapy Market Competitive Dashboard

34. Key Mergers And Acquisitions In The Oligonucleotide Therapy Market

35. Oligonucleotide Therapy Market Future Outlook and Potential Analysis

• 35.1 Oligonucleotide Therapy Market In 2028 - Countries Offering Most New Opportunities
• 35.2 Oligonucleotide Therapy Market In 2028 - Segments Offering Most New Opportunities
• 35.3 Oligonucleotide Therapy Market In 2028 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer